A one-time biotech uni­corn gets slaugh­tered as lead pro­gram is scrapped, high­light­ing lin­ger­ing trou­ble

Back in the balmy mar­ket days of the sum­mer of 2018, Ru­bius Ther­a­peu­tics had every­thing go­ing for it. There was a new plat­form tech in­volv­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.